vimarsana.com

Page 28 - ஆசியா பெஸிஃபிக் தடுப்பூசி நுழைவு வசதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

$9 Billion ADB Facility to Help Members Access and Distribute COVID-19 Vaccines

News Release | 11 December 2020 MANILA, PHILIPPINES (11 December 2020) The Asian Development Bank (ADB) has launched a $9 billion vaccine initiative the Asia Pacific Vaccine Access Facility (APVAX) offering rapid and equitable support to its developing members as they procure and deliver effective and safe coronavirus disease (COVID-19) vaccines. “As ADB’s developing members prepare to vaccinate their people as soon as possible, they need financing to procure vaccines as well as appropriate plans and knowledge to be able to safely, equitably, and efficiently manage the vaccination process,” said ADB President Masatsugu Asakawa. “APVAX will play a critical role in helping our developing members meet these challenges, overcome the pandemic, and focus on economic recovery.”

Community Scoop » $9 Billion ADB Facility To Help Members Access And Distribute Covid-19 Vaccines

World Coronavirus Dispatch: Australia halts local vaccine over HIV concerns

Global infections: 69,619,992 Change Over Yesterday: 663,876 Global deaths: 1,582,342 Nations with most cases: US (15,616,381), India (9,796,769), Brazil (6,781,799), Russia (2,546,113), France(2,391,643). Source: Sanofi-GSK vaccine rollout delayed by poor results for elderly Pharma groups Sanofi and GlaxoSmithKline have said the rollout of their vaccine against Covid-19 will be delayed at least until the last quarter of 2021 because the initial version failed to produce a strong immune response in the elderly. They said that they planned to conduct further studies with an improved antigen formulation, and that the product was now expected to be available in the fourth quarter of next year provided the development plan was completed successfully. Both companies said they were disappointed by the results of the early trials of the vaccine.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.